medicalcondition:hepatitis

  • The Purdue Case Is One in a Wave of Opioid Lawsuits. What Should Their Outcome Be ? | The New Yorker
    https://www.newyorker.com/news/daily-comment/the-purdue-case-is-one-in-a-wave-of-opioid-lawsuits-what-should-their-out

    Two years ago, when I was reporting on the opioid epidemic in one West Virginia county, the exorbitant cost of it—both socially and financially—perpetually astonished me. Narcan, the overdose-reversal drug, yanks people back from the edge of death to live another day and maybe, in time, conquer their addiction. Watching paramedics administer it was like witnessing a miracle over and over again. But Narcan is expensive—it cost Berkeley County, where I was reporting, fifty dollars a dose at the time, and consumed two-thirds of its annual budget for all emergency medications. Since then, the price of naloxone, its generic name, has risen to nearly a hundred and fifty dollars per dose, not because the formula has improved or become costlier to make—the drug has been around since 1961, and off patent since 1985—but because pharmaceutical manufacturers know a profitable market when they see one. According to the National Institute on Drug Abuse, an average of a hundred and thirty people fatally overdose on prescription or illicit opioids every day in the United States. The Centers for Disease Control and Prevention report that four hundred thousand Americans, a war’s worth of dead, died between 1999 and 2017.

    In Berkeley County, though, as in so many places across the country, Narcan accounted for just one column on a staggering spreadsheet. Hospitals have had to care for babies born in withdrawal. Foster-care systems have been strained by an influx of children whose families had been turned upside down by addiction. In many communities, the rates of H.I.V. and hepatitis C have climbed, because, once OxyContin pills were reformulated to make them harder to abuse, in 2010, and changes in prescribing practices made them more difficult to obtain, people addicted to them began injecting heroin and fentanyl instead.

    Under the Master Settlement Agreement, the tobacco companies also committed to pay the states two hundred billion dollars over twenty-five years, and to keep paying them sums tied to cigarette sales in each state in perpetuity. But nothing in the M.S.A. specified how that money was to be spent, and, though one might expect that the bulk of it would be dedicated to the goals of the lawsuits—reducing smoking and promoting public health—that has not generally been the case. In many states, much of the money has gone not to anti-smoking efforts, or even to general spending on health, but instead to closing budget shortfalls, lowering taxes, and funding infrastructure. States treated the agreement like what it felt like: a no-strings-attached gift.

    Je ne suis pas vraiment convainc par la conclusion :

    The Oklahoma settlement with Purdue is a reasonable stab at insuring that the money won in opioid lawsuits doesn’t follow a similar route. Yet some public-health advocates I spoke with said that, in the future, they hope more settlement money will go directly to the treatment of addiction. There’s good evidence, for example, that medication-assisted treatment using buprenorphine, naltrexone, or methadone works well for many people trying to get off opioids, but most states don’t have enough of it.

    Diriger les amendes vers la lutte contre les opioides es tune bonne chose, parce qu’elle évite le pire (que l’amende serve à « baisser les impôts »)... mais cela ne peut pas être un projet dans le cadre des procès. Une fois la responsabilité établie, il faut démanteler ces entreprises et ramener les familles qui les possèdent à un niveau de vie normal, car les Sackler ont largement organisé la promotion d’OxyContin. Or les accords à l’amiable doivent être acceptés par les deux parties, et les construire comme une fin en soi, c’est déjà baisser les bras devant la puissance financière (et donc la qualité/quantité des avocats...). Surtout quand une partie de l’amende sera comme en Oklahoma payée « en nature » par des médicaments produits par Purdue Pharma !!!

    #Opioides #Sackler #Procès

  • Un autre hiver... un de plus...
    Winter conditions add to migrant hardship in northern Greece

    Freezing weather is exacerbating difficult conditions for migrants in overcrowded refugee camps in northern Greece. Last week the cold spell led to a protest by dozens of migrants at a camp near Thessaloniki. Greek officials have blamed the number of people flooding into the camp from the islands and across the Turkish border. But could the situation have been prevented?

    Harsh winter conditions hit northern Greece a few days into the new year, bringing sub-zero temperatures, strong winds, snow and ice. In the Diavata refugee camp near the port city of Thessaloniki, several hundred people are struggling with basic survival. Yet every week, despite the weather conditions, more continue to arrive.

    “They don’t think about this kind of thing, they just want to move on,” said one man at Diavata after another Afghan family arrived in the snow. “They just think that in the next stage from Turkey, when they go to Greece, everything will be fine.”

    Camp protests

    When they reach Diavata, the migrants find the reality is different. The camp is full to capacity, with around 800 registered asylum seekers. On top of these, there are between 500 and 650 people living at the site without having been registered by migration authorities.

    “Most of them have built their own makeshift shelters and tents, which are not providing them with the protection needed,” says Mike Bonke, the Greece country director of the Arbeiter Samariter Bund (ASB), an NGO providing support services to Diavata. “They have no (safe) heating, washing and sanitation and cooking facilities.”

    Last week, the difficult conditions prompted around 40 migrants to hold a protest outside the camp, burning tires and blockading the road. A truck driver tried to get through the barricade resulting in a fight which left one man in hospital.

    The driver lost his patience and started swearing at the migrants, who threw rocks and broke his windscreen, reports said. The driver and four migrants were charged with causing grievous bodily harm, according to the Greek daily, Katherimini.

    Conditions create health concerns

    Diavata is just one of a number of migrant facilities in northern Greece to have been affected by the cold snap. An NGO contacted by InfoMigrants said that Orestiada, near the Evros river to the east, was covered in snow. Migrants in the critically overcrowded camps on the islands too are contending with snow, frozen water pipes and icy roads.

    According to the ASB, the refugee reception camps lack resources to cope with the current conditions. “Healthcare services at all (refugee reception) sites are not adequate,” Bonke says.

    Agis Terzidis, an advisor to the Greek Minister of Health and Vice-President of the Center for Disease Control (CDC) which coordinates healthcare provision to migrants and refugees, admits that the cold weather, in addition to the poor conditions and overcrowding in the camps, is exacerbating migrants’ health problems. “We have people living in conditions that are not acceptable for anyone,” he says.

    National health system must step up

    In response to the worsening situation, there are plans to boost EU-funded medical teams operating in camps throughout the country, including the islands, Agis Terzidis says. But he told InfoMigrants that from now on, more pressure would be put on the Greek national health system and local hospitals to tackle the problem, rather than medical staff in the camps themselves.

    Terzidis also insisted that fixing the situation in the camps was “not in the mandate” of the CDC, as it was chiefly a result of greater numbers of people arriving and consequent overcrowding.

    Instead, the CDC’s main priority remains vaccinating migrants to prevent outbreaks of hepatitis, measles and other infectious diseases. It also focuses on treating those suffering from chronic diseases, some of whom will likely succumb to the harsh winter conditions.

    Too many people

    With more bleak weather predicted, a vegetable garden is being planned in the Diavata camp, giving the residents something to look forward to. That will have to be abandoned if more people start to arrive when the weather improves.

    The camps continue to be under pressure from the large and unpredictable numbers of arrivals. Currently there are around 20 arrivals per week at Diavata, but that could quickly escalate to hundreds. So far, Greek authorities do not seem to have taken steps to limit how many end up at the camps seeking protection.

    I think we can all agree that this situation should have been solved by registering these refugees in the Greek Migration system and providing them with dignified and safe shelters.
    _ Mike Bonke, Greece country director, Arbeiter Samariter Bund

    As both government and army staff and their NGO colleagues in the camps remain powerless to solve the problem of overcrowding, their main task will be to protect migrants from harm and exposure as the winter enters its coldest months.

    http://www.infomigrants.net/en/post/14401/winter-conditions-add-to-migrant-hardship-in-northern-greece
    #Grèce #asile #migrations #réfugiés #camps_de_réfugiés #neige #froid #Salonique #Softex #Diavata #résistance #protestation

  • Viral hepatitis: A silent epidemic killing more people than HIV, ma...
    https://diasp.eu/p/8157219

    Viral hepatitis: A silent epidemic killing more people than HIV, malaria or TB

    Viral hepatitis is on the rise. Tackling hepatitis B in Africa is key to fighting back. Article word count: 2534

    HN Discussion: https://news.ycombinator.com/item?id=18627683 Posted by pseudolus (karma: 2692) Post stats: Points: 153 - Comments: 63 - 2018-12-07T14:03:41Z

    #HackerNews #epidemic #hepatitis #hiv #killing #malaria #more #people #silent #than #viral

    Article content:

    Nuru was prepared for the worst when she went to get screened for HIV eight years ago. After caring for her mother in Uganda, who died as a result of the virus, Nuru moved to the United Kingdom to study, and decided to take her health into her own hands. “I was ready to be told I had HIV,” she says. “I felt, ‘That’s okay. I’ve (...)

  • “Is curing patients a sustainable business model?” Goldman Sachs analysts ask | Ars Technica
    https://arstechnica.com/tech-policy/2018/04/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-

    One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

    The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.

    Analyst Salveen Richter and colleagues laid it out:

    The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.

    For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.

    “[Gilead]’s rapid rise and fall of its hepatitis C franchise highlights one of the dynamics of an effective drug that permanently cures a disease, resulting in a gradual exhaustion of the prevalent pool of patients,” the analysts wrote. The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business.

  • Pharmaceutical industry gets high on fat profits - BBC News
    https://www.bbc.com/news/business-28212223

    Last year, US giant Pfizer, the world’s largest drug company by pharmaceutical revenue, made an eye-watering 42% profit margin. As one industry veteran understandably says: “I wouldn’t be able to justify [those kinds of margins].”

    Stripping out the one-off $10bn (£6.2bn) the company made from spinning off its animal health business leaves a margin of 24%, still pretty spectacular by any standard.

    In the UK, for example, there was widespread anger when the industry regulator predicted energy companies’ profit margins would grow from 4% to 8% this year.

    Last year, five pharmaceutical companies made a profit margin of 20% or more - Pfizer, Hoffmann-La Roche, AbbVie, GlaxoSmithKline (GSK) and Eli Lilly.

    Drug companies justify the high prices they charge by arguing that their research and development (R&D) costs are huge. On average, only three in 10 drugs launched are profitable, with one of those going on to be a blockbuster with $1bn-plus revenues a year. Many more do not even make it to market.

    But as the table below shows, drug companies spend far more on marketing drugs - in some cases twice as much - than on developing them. And besides, profit margins take into account R&D costs.

    The industry also argues that the wider value of the drug needs to be considered.

    “Drugs do save money over the longer term,” says Stephen Whitehead, chief executive of the Association of the British Pharmaceuticals Industry (ABPI).

    "Take hepatitis C, a shocking virus that kills people and used to require a liver transplant. At £35,000 [to £70,000] for a 12-week course, 90% of people are now cured, will never need surgery or looking after, and can continue to support their families.

    “The amount of money saved is huge.”

    Pour les opioides, c’est le contraire... les coûts sociaux sont largement plus importants que les revenus des entreprises pharmaceutiques concernées.

    Courting doctors

    But drug companies have been accused of, and admitted to, far worse.

    Until recently, paying bribes to doctors to prescribe their drugs was commonplace at big pharmas, although the practice is now generally frowned upon and illegal in many places. GSK was fined $490m in China in September for bribery and has been accused of similar practices in Poland and the Middle East.

    The rules on gifts, educational grants and sponsoring lectures, for example, are less clear cut, and these practices remain commonplace in the US.

    Indeed a recent study found that doctors in the US receiving payments from pharma companies were twice as likely to prescribe their drugs.

    ’Undue influence’

    No wonder, then, that the World Health Organisation (WHO) has talked of the “inherent conflict” between the legitimate business goals of the drug companies and the medical and social needs of the wider public.

    Indeed the Council of Europe is launching an investigation into “protecting patients and public health against the undue influence of the pharmaceutical industry”.

    It will look at “particular practices such as sponsoring health professionals by the industry... or recourse by public health institutions to the knowledge of highly specialised researchers on the pay-rolls of industry”.

    #Pharmacie #Marketing

  • Goldman Sachs report : « Is curing patients a sustainable business model ? » / Boing Boing
    https://boingboing.net/2018/04/14/shared-microbial-destiny.html
    Soigner les pauvres est seulement rentable s’ils demeurent malades.

    In Goldman Sachs’s April 10 report, “The Genome Revolution,” its analysts ponder the rise of biotech companies who believe they will develop “one-shot” cures for chronic illnesses; in a moment of rare public frankness, the report’s authors ask, “Is curing patients a sustainable business model?”

    The authors were apparently spooked by the tale of Gilead Sciences, who developed a Hepatitis C therapy that is more than 90% effective, making $12.5B in 2015 — the year of the therapy’s release — a number that fell to $4B this year.

    The analysts are making a commonsense observation: capitalism is incompatible with human flourishing. Markets will not, on their own, fund profoundly effective cures for diseases that destroy our lives and families. This is a very strong argument for heavily taxing the profits of pharma companies’ investors and other one percenters, and then turning the money over to publicly funded scientific research that eschews all patents, and which is made available for free under the terms of the Access To Medicines treaty, whereby any country that devotes a set fraction of its GDP to pharma research gets free access to the fruits of all the other national signatories.

    Humans have shared microbial destiny. If there’s one thing that challenges the extreme libertarian conception of owing nothing to your neighbor save the equilibrium established by your mutual selfishness, it’s epidemiology. Your right to swing your fist ends where it connects with my nose; your right to create or sustain reservoirs of pathogens that will likely kill some or all of your neighbors is likewise subject to their willingness to tolerate your recklessness.

    Goldman Sachs’s analysts suggest three “cures” for the problem of one-shot cures; and taxing the rich to fund socialized pharma research isn’t among them; rather, they propose eschewing rare diseases, to ensure that the pool of patients is large enough to produce a return on their investment, or developing one-shot cures fast enough to “offset the declining revenue trajectory of prior assets.”

    #capitalisme #santé

  • Goldman asks: ’Is curing patients a sustainable business model?’
    https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html

    “Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”

    “The potential to deliver ’one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

    (…) “GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”

    #économie #recherche #pharma #biens_publics #merci @archiloque

  • The Battle of 1498 | Alternet
    https://www.alternet.org/personal-health/battle-1498

    Hepatitis C is a blood virus that affects 3.5 million Americans and kills more of them than every other virus combined. So when $62 million in government basic research led to the direct-action drug sofosbuvir, which successfully treats the disease, Hep C advocates thought global eradication might be at hand.
    Report Advertisement

    Then something awful happened: the patent-and-profit system worked exactly as designed.

    In 2011, the California-based drug giant Gilead bought the small bio-med company then in the process of bringing sofosbuvir through trials. When Gilead introduced sofosbuvir to market a few years later, it came with a price tag upwards of $100,000; even with discounts, the drug was priced well beyond the reach of most people. It also strained and busted Medicaid budgets across the country.

    Gilead and Janssen, the other company selling patented Hep C treatments, have since made more than $70 billion selling the new Hep C drugs, which happen to be incredibly cheap to produce. How cheap? So cheap, one study estimates they can be produced for between $62 and $216; another study, conducted at Liverpool University, places the cost below $100.

    Khanna continued, “The Hep C drugs present a pretty simple moral issue that highlights the need for reform. When the vast majority of scientific research in this country is being done at universities with NIH funding supported by taxpayer money, we shouldn’t be privatizing the gains. Millions of people need these drugs. We need to prioritize the public good.”

    #Big_Pharma #Hépatite_C #Brevets #Propriété_intellectuelle

  • San Diego is struggling with a huge hepatitis A outbreak. Is it coming to L.A.? - LA Times
    http://www.latimes.com/local/california/la-me-hepatitis-los-angeles-20170914-htmlstory.html
    http://www.trbimg.com/img-59bcaea9/turbine/la-me-hepatitis-los-angeles-20170914

    Health officials in San Diego have scrambled for months to contain an outbreak of hepatitis A — vaccinating more than 19,000 people, putting up posters at bus stations and distributing hand sanitizer and cleansing wipes.

    Despite those efforts, 16 people have died of the highly contagious virus in San Diego County and hundreds have become ill in what officials say is the nation’s second-largest outbreak of hepatitis A in decades.

    Earlier this month, San Diego officials declared a public health emergency.

    Though Los Angeles has so far escaped an outbreak, public health officials are hoping to head off a similar emergency. They say the virus could easily spread to Los Angeles because of its proximity to San Diego and the region’s large homeless population.

    C’est effrayant la quantité de sans-abris en Californie, une des régions les plus riches de la planète... et les conditions sanitaires qui se dégradent pour eux ont des conséquences sur toute la ville. Enjeu du nettoyage à l’eau de javel.

    #Santé_publique #Nettoyage_villes #Municipalités #Sans_abris

  • US health care tab hits $3.2T; fastest growth in 8 years
    https://apnews.com/248e6a59703f4e1c92200f2df0082d02

    Spending on prescription drugs dispensed through pharmacies increased by 9 percent in 2015. Although that rate of growth was less than in 2014, the report said drug spending grew faster any other category, including hospitals and doctors. It wasn’t only pricey new drugs for hepatitis C infection driving the trend, but also new cancer drugs and price increases for older brand-name and generic drugs.

    #pharma #big_pharma #Etats-Unis #santé

  • Hepatitis A outbreak linked to smoothies spans 5 states; 51 sick | Food Safety News
    http://www.foodsafetynews.com/2016/08/hepatitis-a-outbreak-linked-to-smoothies-spans-5-states-51-sick

    More than 50 people in five states are confirmed with Hepatitis A infections in an outbreak associated with frozen strawberries from Egypt that were served at Tropical Smoothie Café locations in Virginia.

    The vast majority of the infected people — 44 — are Virginia residents, according to the Virginia Department of Health and the federal Centers for Disease Control and Prevention. There are also four confirmed victims in Maryland and one each in North Carolina, Oregon and Wisconsin, a CDC spokeswoman said Tuesday.
    […]
    Virginia officials notified the Tropical Smoothie Café chain at that point, but did not alert the public for another two weeks.

    On Aug. 5 the Virginia Department of Health contacted us about a potential link between Hepatitis A cases and frozen strawberries from Egypt,” CEO Mike Rotondo says in a YouTube video posted Sunday by Tropical Smoothie Café.

    The restaurant chain immediately removed the implicated fruit from all of its locations, Rotondo says in the video. Tropical Smoothie is now sourcing strawberries from California and Mexico.

    While pulling the implicated strawberries may have reduced the number of outbreak victims, some Tropical Smoothie customers likely could have been spared infection if Virginia officials had not waited 14 days before alerting the public.

    That two-week delay is key because of the narrow window of opportunity for post-exposure vaccination. The post-exposure Hepatitis A vaccine, or immune globulin (IG) injections, must be administered within 14 days of exposure or they are not effective, according to Virginia health officials and CDC.

  • Public Health Experiment Brings Hepatitis Cures to Egypt’s Poor
    http://www.nytimes.com/2015/12/16/health/hepatitis-c-treatment-egypt.html

    Once demonized for withholding lifesaving AIDS drugs from poor countries in Africa, chastened pharmaceutical companies are testing an alternative strategy: a complicated deal to sell hepatitis drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West.

    The strategy has raised howls of outrage from public health advocates in some quarters. If it succeeds, though, the arrangement in Egypt may serve as a blueprint not just for curing hepatitis around the world, but also for providing other cutting-edge medicines to citizens in poor countries who could never afford them.

    #Egypte #santé #hépatite #vaccin #pauvres #pharma

  • Drug Goes From $13.50 a Tablet to $750, Overnight
    http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html

    Turing’s price increase is not an isolated example. While most of the attention on pharmaceutical prices has been on new drugs for diseases like cancer, hepatitis C and high cholesterol, there is also growing concern about huge price increases on older drugs, some of them generic, that have long been mainstays of treatment.

    #pharma « #marché » #santé #prix #médicaments #Etats-Unis

  • At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt - Bloomberg
    http://www.bloomberg.com/news/2014-01-27/at-84-000-gilead-hepatitis-c-drug-sets-off-payer-revolt.html

    As Gilead Sciences Inc. (GILD) touted its $1,000-a-pill hepatitis C cure to investors in a hotel ballroom in San Francisco, a group of about 20 protesters milled outside. “Gilead=Greed,” one sign read.

    (...) worries that insurers will see Gilead’s price and force patients to try a less effective, older and cheaper therapy first (...)

    Gilead’s new drug, Sovaldi, costs $84,000 for a 12-week treatment. Such breakthrough treatments and their stratospheric price tags have “absolutely” caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments,

    #hépatite #santé #pharma #médicaments #prix

  • Pakistan Battles Polio, and Its People’s Mistrust - NYTimes.com
    http://www.nytimes.com/2013/07/22/health/pakistan-fights-for-ground-in-war-on-polio.html

    Pourquoi l’UNICEF et l’OMS n’ont pas réagi au scandale de l’utilisation par le régime étasunien de la campagne de vaccination pour traquer OBL.

    In the middle of last year, it became known that in 2011, the C.I.A. had paid a local doctor to try to get DNA samples from children inside an Abbottabad compound to prove they were related to Bin Laden. Even though the doctor, Shakil Afridi, who is now serving a 33-year sentence for treason, was offering a hepatitis vaccine, anger turned against polio drops. Leaders of the polio eradication effort could not have been more frustrated. They were already fighting new rumors that vaccinators were helping set drone targets because they have practices like marking homes with chalk so that follow-up teams can find them. Now, after years of reassuring nervous families that the teams were not part of a C.I.A. plot, here was proof that one was. “It was a huge, stupid mistake,” Dr. Bhutta said. Anger deepened when American lawmakers called Dr. Afridi a hero and threatened to cut off aid if he was not released.

    The W.H.O. and the Unicef, afraid of offending the United States, did not protest publicly. Unicef’s executive director, Anthony Lake, is a former White House national security adviser, which put the agency in an awkward position, an agency official said on the condition of anonymity because of the sensitivity of the issue."

  • Hepatitis C drug trial halted after patient death | Nature
    http://blogs.nature.com/news/2012/08/hepatitis-c-drug-trial-halted-after-patient-death.html

    Bristol-Myers Squibb has halted development of a potential hepatitis C drug after nine participants in a clinical trial of the therapy were hospitalised and one died (see press release).
    (...)
    Bristol-Myers Squibb (BMS) acquired the rights to the drug BMS-986094 (formerly known as INX-189) when it bought Inhibitex of Alpharetta, Georgia for US$2.5 billion in January (see ‘Pharma giants buy up hepatitis C hopefuls’).
    (...) Abandoning the drug amounts to writing off about $1.8 billion of what BMS paid for Inhibitex. After the news of the safety crisis broke, shares in BMS fell, reducing its market value by billions (see Fierce Biotech).

    #pharma #essais #finance

  • Gilead to Share 4 AIDS and Hepatitis Drugs With Patent Pool - NYTimes.com
    http://www.nytimes.com/2011/07/12/health/12global.html?_r=1

    In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool.
    (...)
    “This is a great achievement,” said James P. Love, a campaigner for lower drug prices who first proposed a pool in 2002. “The other drug companies didn’t want Gilead to sign anything, and this will put pressure on them.”

    #santé #pharma #brevets